The announcement of a substantial cash reserve and marketable securities for Intellia Therapeutics indicates a strong financial health and operational stability for the near future. This reduces the immediate risk of dilutive fundraising and provides confidence to investors about the company's ability to sustain its operations and research activities without financial strain. Such positive financial news is likely to be viewed favorably by the market, potentially leading to an increase in stock price in the short term.